For drug development, species differences in drug-metabolism reactions present obstacles
for predicting pharmacokinetics in humans. We characterized the species differences in …

The cynomolgus monkey is a nonhuman primate that is often used for pharmacokinetic and
toxicokinetic studies of new chemical entities. Species differences in drug metabolism are …

Abstract Carboxylesterase (CES) 1, CES2, and arylacetamide deacetylase (AADAC) are the
major drug hydrolases in humans, and they have different substrate preferences. Because …

Cynomolgus monkeys, used as an animal model to predict human pharmacokinetics,
occasionally show different oral absorption patterns to humans due to differences in their …

In contrast to a single human carboxylesterase 2 (CES2) isozyme (hCE2), three CES2
genes have been identified in cynomolgus monkeys: mfCES2A, mfCES2B, and mfCES2C …

Carboxylesterase (CES) and arylacetamide deacetylase (AADAC) are the major enzymes
responsible for the hydrolysis of various clinical drugs. Our recent study demonstrated that …

Background: Carboxylesterases (CES) play a critical role in catalyzing hydrolysis of esters,
amides, carbamates and thioesters, as well as bioconverting prodrugs and soft drugs. The …

The carboxylesterases (CESs) are a family of serine hydrolases that hydrolyze compounds
containing an ester, amide, or thioester. In humans, two dominant forms, CES1 and CES2 …

Carboxylesterase (CES) is important for detoxification of a wide range of drugs and
xenobiotics and catalyzes cholesterol and fatty acid metabolism. Cynomolgus macaques are …

The age-associated alteration in expression levels of carboxylesterases (CESs) can affect
both intestinal and hepatic first-pass metabolism after oral administration of xenobiotic esters …